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Abstract
Background: Lassa fever (LF) is a devastating hemorrhagic viral disease that is endemic to West Africa and
responsible for thousands of human deaths each year. Analysis of humoral immune responses (IgM and IgG) by
antibody-capture ELISA (Ab-capture ELISA) and Lassa virus (LASV) viremia by antigen-capture ELISA (Ag-capture
ELISA) in suspected patients admitted to the Kenema Government Hospital (KGH) Lassa Fever Ward (LFW) in Sierra
Leone over the past five years is reshaping our understanding of acute LF.
Results: Analyses in LF survivors indicated that LASV-specific IgM persists for months to years after initial infection.
Furthermore, exposure to LASV appeared to be more prevalent in historically non-endemic areas of West Africa
with significant percentages of reportedly healthy donors IgM and IgG positive in LASV-specific Ab-capture ELISA.
We found that LF patients who were Ag positive were more likely to die than suspected cases who were only IgM
positive. Analysis of metabolic and immunological parameters in Ag positive LF patients revealed a strong
correlation between survival and low levels of IL-6, -8, -10, CD40L, BUN, ALP, ALT, and AST. Despite presenting to
the hospital with fever and in some instances other symptoms consistent with LF, the profiles of Ag negative IgM
positive individuals were similar to those of normal donors and nonfatal (NF) LF cases, suggesting that IgM status
cannot necessarily be considered a diagnostic marker of acute LF in suspected cases living in endemic areas of
West Africa.
Conclusion: Only LASV viremia assessed by Ag-capture immunoassay, nucleic acid detection or virus isolation
should be used to diagnose acute LASV infection in West Africans. LASV-specific IgM serostatus cannot be
considered a diagnostic marker of acute LF in suspected cases living in endemic areas of West Africa. By applying
these criteria, we identified a dysregulated metabolic and pro-inflammatory response profile conferring a poor
prognosis in acute LF. In addition to suggesting that the current diagnostic paradigm for acute LF should be
reconsidered, these studies present new opportunities for therapeutic interventions based on potential prognostic
markers in LF.
Background
LASV is a member of the Arenaviridae family and is the
etiologic agent of LF, which is an acute and often fatal
illness endemic in West Africa. There are an estimated
300,000 - 500,000 cases of LF each year [1-7] with a
reported mortality rate of 15%-20% for hospitalized
patients. Mortality rates for LF can become as high as
50% during epidemics [3,8,9] and 90% in third trimester
pregnancies for both the expectant mother and the
fetus. Presently, there is no licensed vaccine or immu-
notherapy available for prevention or treatment of this
disease. The severity of LF, its ability to be transmitted
via aerosol droplets [10], and the lack of a vaccine or
therapeutic drug led to its classification as a National
Institutes of Allergy and Infectious Diseases (NIAID)
Category A pathogen and biosafety level-4 (BSL-4)
agent. The antiviral drug ribavirin has been demon-
strated to reduce fatality from 55% to 5%, but only if it
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is administered within 6 days after the onset of symp-
toms [1,8,9]. There is currently no commercially avail-
able LF diagnostic assay, which presents a major
challenge for early detection and rapid implementation
of existing treatment regimens.
Since 2005, continuous infrastructure improvements at
the KGH Lassa Fever Laboratory (LFL) by the National
Institutes of Health (United States), the Department of
Defense (DoD), the Naval Facilities Engineering Com-
mand (NAVFAC), the United States Army Medical
Research Institute of Infectious Diseases (USAMRIID),
the World Health Organization (WHO), Global Viral
Forecasting (GVF) and Tulane University have resulted
in the implementation of sophisticated, on-site diagnos-
tic and research capabilities [11,12]. Currently, LF is
diagnosed at the KGH LFL using ELISA and lateral flow
immunoassays (LFI) that detect viral Ag. Virus-specific
IgM and IgG levels are also determined in serum sam-
ples for all suspected cases that present to the KGH
LFW. Additionally, the laboratory assesses 14 serum
analytes using a Piccolo® blood chemistry analyzer
coupled with comprehensive metabolic panel disks. Flow
cytometry powered by a 4-color Accuri® C6 cytometer
performs immunophenotyping, intracellular cytokine
and bead-based secreted cytokine analysis on patient
sera. These resources contributed to advances in real
time diagnosis along with metabolic and immunological
characterization of acute LF, thus resulting in a marked
improvement in the management of the disease. Herein
we present evidence that introduces new insight into
humoral and cellular immune responses to LASV that
have lead us to reevaluate the role of LASV IgM seropo-
sitivity in diagnosing acute LF in suspected cases living
in the LASV endemic areas of West Africa. An
improved understanding of the natural history of LF will




Suspected LF patients, individuals reporting close con-
tact with confirmed LF patients, and healthy volunteers
were eligible to participate in these studies as outlined
in Tulane University’s Institutional Review Board (IRB)
protocol, National Institutes of Health/National Insti-
tutes of Allergy and Infectious Diseases (NIH/NIAID)
guidelines governing the use of human subjects for
research, and Department of Health and Human Ser-
vices (HHS)/NIH/NIAID Challenge and Partnership
Grant Numbers AI067188 and AI082119 and HHS Con-
tract HHSN272200900049C. The Tulane University IRB
has approved these projects. All subjects participating in
the study gave written informed consent to the publica-
tion of their case details.
Sera from suspected LF patients and healthy volunteers
Small blood volumes (typically five milliliters [mL]), for
serum separation were collected from study subjects
with consent from the attending physician. Blood from
healthy Sierra Leonean volunteers were used as normal
controls. Three groups of normal donors were
assembled for this study: 1) non-febrile volunteers com-
prised of Lassa program staff from Kenema district and
nursing staff from a hospital in Bo, Sierra Leone, who
reported to be in generally good health at the time of
blood collection; 2) volunteers from randomly-chosen,
historically non-endemic villages in the District of
Moyamba (N = 101) and the District of Bombali (N =
13) that also reported to be in generally good health,
not having any recent illnesses or having travelled to
Africa’s Eastern Province. Both patients and healthy
volunteer samples received a coded designation and
were collected in serum vacutainer tubes and allowed to
coagulate for 20 minutes at room temperature. Serum
was separated from coagulated blood by centrifugation
(200 × g, 20 minutes at room temperature). The serum
fraction was collected for analysis, and aliquots were
stored in cryovials at -20°C. Sera from a panel of 50 ran-
domized U.S. male donors were purchased from Biore-
clamation, Inc. (Westbury, NY), and a similar panel of
50 U.S. female donors was obtained from SeraCare Life
Sciences, Inc. (Milford, MA). All U. S. donors were at
least 18 years of age and reported their ethnic groups as
Caucasian, Hispanic, or African American.
Patient database analysis
A database was generated with coded patient designa-
tions and corresponding LASV antigen, IgM and IgG
status at the time of testing and admission. In total
1,909 suspected LF patient data were collected and a
subset of those data were used in this study. All patients
in the database were suspected of having LF based on
clinical presentation, or for failure to respond to anti-
malarial and/or antibiotic drug regimens over the course
of a prolonged febrile illness.
Detection of LASV antigen by LFI, ELISA and PCR
Serum levels of LASV nucleoprotein (NP)-specific Ag
were measured using LASV Antigen Rapid Test cas-
settes and dipstick LFI currently under pre-clinical
development by Corgenix Medical Corp. (Broomfield,
CO) and the Viral Hemorrhagic Fever Consortium (see
acknowledgements), as described by Grove et al. [11].
Positive LF diagnosis was confirmed with a sensitive Ag-
capture ELISA employing either a murine monoclonal
or caprine polyclonal capture antibody (Autoimmune
Technologies, L.L.C., New Orleans, LA) followed by a
peroxidase-labeled caprine reagent and tetramethylben-
zidine (TMB) substrate, as previously outlined by Grove
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et al. [11]. Both methods were substantiated with a RT-
PCR test. RNA was extracted from serum using a
QIAmp Viral RNA Mini kit (QIAGEN, Valencia, CA).
RT-PCR was performed using SuperScript III (Invitro-
gen, Carlsbad, CA) with primers 36E2 and 80F2 or LVS-
339-rev directed against the LASV glycoprotein complex
(GPC) gene for amplification of a highly conserved 318
nucleotide fragment (Lassa virus Josiah positions 4 to
322 of S RNA) [13].
Detection of LASV-specific serum IgM and IgG levels by
ELISA
Individual recombinant LASV (reLASV) proteins
(Vybion, Inc., Ithaca, NY; The Scripps Research Institute,
La Jolla, CA; AutoImmune Technologies, LLC, New
Orleans, LA; Tulane University Health Sciences Center,
New Orleans, LA) and combinations of reLASV proteins
optimized for detection of virus-specific IgM and IgG
levels in serum were coated in stripwell plates at Cor-
genix Medical Corp. and packaged as test kits. Detection
of LASV-specific IgM and IgG in suspected LF patient
and normal control sera was performed as previously
outlined by Grove et al. [11]. IgM binding specificity in
Moyamba and Bombali normal donors was confirmed by
western blot on LASV NP and by competition assays
with sera spiked with recombinant NP in ELISA. Similar
assays were performed to ascertain IgG binding specifi-
city. Additionally, normal and LF patient sera were
depleted of IgG with ProteaPrep IgG Depletion Sample
Prep Kits (Protea, Morgantown, WV), as per manufac-
turer recommendations. Binding of LASV-specific IgG
and IgM were re-assessed by ELISA after IgG depletion.
Comprehensive Metabolic Panel analysis
The kinetics of fourteen serum analytes were analyzed
with a Piccolo® blood chemistry analyzer (Abaxis, Inc.,
Union City, CA) and Comprehensive Metabolic Reagent
Discs, as per manufacturer’s recommendations.
Cytokine profiles
Profiles of eleven serum cytokines were analyzed with an
Accuri C6® benchtop cytometer (Accuri Cytometers
Inc., Ann Harbor, MI) and an eBioscience FlowCytomix
Human Th1/Th2 11-plex Kit (Bender MedSystems
GmbH, Vienna, Austria). Additionally, VEGF-A, CRP,
RANTES, IFN-a, and CD40L simplex kits were multi-
plexed for analysis of additional ligands. Serum aliquots
collected and frozen throughout the experimental time-
line were analyzed concurrently at the end of the study.
Laboratory confirmation of LF
All serum samples were tested for LASV-specific Ag and
IgM and IgG antibodies by ELISA, as outlined above.
ReLASV NP was serially diluted and used to generate a
standard curve in Ag-capture ELISA and LFI formats.
Sera from previously diagnosed LF patients were used as
IgM and IgG Ab-capture ELISA calibrators. As dis-
cussed in detail herein, patients who presented to the
KGH LFW with a febrile illness were assessed by the
following criteria: Patients were considered to have
acute LF if a reaction above background levels devel-
oped on reLASV LFI modules and/or LASV Ag-capture
ELISA, and/or LASV-specific RT-PCR generated a GPC
gene-specific amplicon using oligonucleotides previously
described by Olschläger et al. [13]. Subjects testing only
as IgM+ using reLASV IgM Ab-cature ELISA were not
considered acute LF cases and often were not adminis-
tered a course of ribavirin. The ultimate decision to
administer a course of ribavirin to Ag-IgM+ patients
was at the discretion of the attending KGH LFW physi-
cian. Subjects testing only as IgG+ using reLASV IgG
were also not considered acute cases, but rather were
considered to have been previously exposed to LASV
and were deemed to be suffering from a non-Lassa feb-
rile illness. Similarly, patients who were dual IgM+IgG+
and LASV Ag- at the time of testing were considered to
be suffering from an unrelated febrile illness. For these
patients additional testing and disease diagnosis was per-
formed, as per the capabilities available at the KGH.
Assignment to LF status groups
Patients were assigned to one of five groups on the basis
of LASV Ag status, IgM and IgG profiles, and outcome.
Group assignment was largely based on real-time data
at the time of testing or admission to the KGH, and in a
few cases the course of illness was followed into early
convalescence [11,13]. The five groups were designated
as: (1) Lassa fever, non-fatal, Ag+ (LF NF; N = 19); (2)
Lassa fever, fatal, Ag+ (LF F; N = 25); (3) uninfected or
afebrile controls (normal; N = 15); (4) Lassa fever, non-
fatal, follow up patients sampled at least 8 weeks after
discharge (LF FU; N = 18); and (5) LASV Ag-, IgM+,
febrile patients (NL FI IgM+; N = 21). An additional
group was analyzed that was comprised of individuals
admitted to KGH with a non-Lassa febrile illness and a
nonfatal outcome, irrespective of LASV-specific Ig status
(NL FI NF; N = 37). The status of LASV Ag and IgM
and IgG antibody profiles in populations from histori-
cally non-endemic LF areas of Sierra Leone were deter-
mined by ELISA as outlined above, but cytokines and
metabolic markers were not analyzed for this subset of
donors (Moyamba normals [MOY NHS]: N = 101; Bom-
bali normals [BOM NHS]: N = 13).
Statistical methods
Detection and measurement
ELISA data were plotted as mean ± SD, where each
mean was based on two replicates, and error bars were
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used to represent the standard deviations. Limits of
detection and quantitation of LASV-specific IgM were
based on the upper 95th percentile obtained with a
panel of sera from U.S. (USN) and Sierra Leonean
donors without detectable LASV Ag, IgM, and IgG
titers. Cytokine levels were calculated by applying curve
fitting techniques to data generated with quantified
standards for each analyte.
Statistical analysis
Box plots of IgM and IgG serum responses were gener-
ated for seven comparison groups: USN, MOY NHS,
BOM NHS, LF FU, LF NF, LF F, and NL FI IgM+. Box
plots of serum responses for IgM and IgG profiles were
generated using the Vertex42 Microsoft Excel template
[14]. The Kruskal-Wallis test was used to compare med-
ian serum responses among the six comparison groups,
and subsequent pairwise comparisons were conducted
using Dunn’s post test. Wilcoxon’s signed rank test was
used to assess changes in median IgM and IgG serum
levels between baseline and follow-up end points. Sim-
ple linear regression was used to assess the relationship
between IgM and IgG serum level responses and the
number of days post discharge. The response data for
these regression models was log-transformed to conform
to linear regression assumptions. The Kruskal Wallis
procedure was used to compare median NP Ag serum
levels among the LF FU, LF NF, and the LF F groups.
Logistic regression models were used to make patient
subgroup comparisons with respect to survival outcome.
All of the statistical analyses were conducted using
GraphPad InStat 3 (GraphPad Software, Inc., San Diego,
CA) and the SAS System (SAS Institute, Inc., Cary, NC)
[15]. The statistical significance threshold for all of the
analyses was set at p < 0.05.
Results
Odds of fatal outcome by test result in suspected LF
patients
Survival data from a database comprised of 1,909 sus-
pected LF patients who were tested for LASV Ag and
IgM at the KGH LFL from 2007 - 2011 is summarized
in Table 1 (N = 546). The patients for whom we had
survival outcome were grouped according to Ag and
IgM status. Odds ratios revealed that febrile patients
who presented to the KGH LFW with LASV-specific Ag
were statistically more likely to die than febrile patients
who had no detectable Ag. These data are irrespective
of IgM status. Patients who were both Ag and IgM posi-
tive were 4.33 times more likely to die than those who
presented with an IgM+ titer, but no LASV Ag (p <
0.01). Similarly, Ag+ patients with no IgM upon admis-
sion were 5.36 times more likely to die than those who
presented with neither Ag nor IgM titers (p < 0.01). We
found no statistical difference between patients who had
the same Ag status, again, irrespective of IgM. Both Ag+
groups (Ag+IgM+, Ag+IgM-) were nearly equally likely
to die (p = 0.83), while both Ag- groups (Ag-IgM+, Ag-
IgM-) where similarly likely to live (p = 0.61). IgM sta-
tus, therefore, does not appear to impact survival out-
come. Only 5 patients of this large cohort have
presented to the KGH LFW with an Ag+ IgM- IgG+
profile: Four patients survived and one succumbed.
Ag levels differ significantly between fatal and non-fatal
LF
LASV NP Ag levels were measured in the serum of sus-
pected LF patients by LFI, ELISA, PCR, or a combina-
tion of the three methods. Quantitative LASV NP Ag-
capture ELISA was used to quantify levels of NP in LF
patients. At the time of admission NP Ag levels between
eventual fatal and non-fatal LF patients were statistically
different (p < 0.01; Figure 1). Thus, Ag levels at time of
admission could be used as a prognostic marker.
Characteristics of LF patients, normal participants, and
other non-LF febrile subjects
Characteristics of our study subjects are shown in Table
2 and Additional File 1. The average age for nonfatal
and fatal LF patients was 28.3 and 18.7 years, respec-
tively. No significant characteristic differences in charac-
teristics between the LF F and LF NF groups were
observed, except for duration of illness. Patients who
Table 1 Odds of fatal outcome by LASV-specific NP Ag- and Ab-capture ELISA
Test Result N (% fatal) Comparison Group Adjusted OR (95% CI)a p
Ag+IgM+ 35 (54) Ag-IgM+ 4.33* (2.01, 9.30) < 0.01
Ag+IgM- 96 (56) Ag-IgM- 5.36* (3.19, 9.00) < 0.01
Ag+IgM+ 1.09 (0.50, 2.40) 0.83
Ag-IgM+ 171 (22) Ag-IgM- 1.13 (0.70, 1.83) 0.61
Ag-IgM- 244 (20) - - -
a Odds of fatal outcome relative to the comparison group; all Ors are adjusted for gender.
* Statistically significant at the 5% significance level.
Individuals who presented to the KGH LFW were tested for LF by Ag- and Ab-capture ELISA. We subsequently categorized individuals based on LASV Ag and Ab
status. Fatality comparisons of Ag+IgM+, Ag+IgM-, Ag-IgM+, and Ag-IgM- individuals revealed that there was no significant difference between Ag-status groups
irrespective of IgM status. Conversely, Ag+ patients were about 5 times more likely to succumb than Ag- patients irrespective of IgM status (p < 0.01).
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survived to at least day three after admission at KGH
LFW were at least 5.2 times more likely to survive
(Table 2, Additional File 1). The odds ratio for the
bleeding characteristic indicates a potential affect on
survival outcome (OR = 5.1), but this study lacked a suf-
ficient number of patients presenting bleeding symp-
toms to show statistical significance (Table 2, Additional
File 1). A subset of patients presenting with either fever,
bleeding, conjunctivitis, or a combination of symptoms,
who tested negative for LASV Ag and positive for IgM
(and mostly negative for LASV-specific IgG) were com-
pared with Ag+ confirmed LF cohorts. The NL FI group
was comprised of 37 febrile patients, with 21/37 (57%)
registering significant LASV IgM titers (Additional File
1). We saw significant differences in the duration of
illness and bleeding categories between LF F cases and
NL FI IgM+ cases. The odds ratio indicated that an Ag-
IgM+ (NL FI IgM+) individual who survived to at least
day three of admission at the KGH was at least 2.48
times more likely to survive than an Ag+ individual
(Table 2, Additional File 1). Also, an Ag+ patient who
succumbed to LF was at least 1.09 times more likely to
have bleeding symptoms than one who is negative for
Ag (NL FI) and positive for IgM (Table 2, Additional
File 1). A complete list of OR for each characteristic is
displayed in Additional File 1.
Immunoglobulins in convalescent, nonfatal, and fatal LF
The levels of LASV-specific serum IgM and IgG were
compared among U.S. and West African normal con-
trols (USN, MOY NHS and BOM NHS, respectively),
surviving LF patients (LF FU), acute fatal and nonfatal
LF patients, and febrile LASV Ag-IgM+ subjects (Fig-
ure 2). Additionally, LF FU IgM and IgG titers were
measured for months to years into convalescence (Fig-
ure 3). These comparisons were aimed at establishing
(1) how long into convalescence LASV-specific IgM
levels persist; (2) if humoral responses between fatal
and nonfatal LF differed significantly at time of admis-
sion and testing, thus serving as a prognostic marker;
(3) if surviving LF patients mounted a significant
humoral response during treatment that subsides upon
recovery from acute infection. Studies on LF carried
out between 2006 and 2011 revealed LASV-specific
IgM levels persist in convalescence lasting from
months to years after initial infection (Figure 3A). In
this study, we analyzed the immunological and meta-
bolic response in 34 LF convalescent patients who
donated whole blood for analysis between 8 weeks and
2.2 years post-discharge. The mean time between dis-
charge and follow-up analysis for these donors was 263
± 221 days (ranging from 51 to 785 days). Corrected
levels of LASV-specific IgM did not correlate linearly
with time post discharge (R2 < 0.0001, p = 0.986), sug-
gesting that IgM does not subside rapidly following the
rise of IgG titers in convalescence (Figure 3B). Simi-
larly, LASV-specific IgG levels did not correlate line-
arly with time post discharge (R2 = 0.0195, p = 0.431).
A moderate to high level of IgG was recorded in all
follow-up sera (Figure 2B, 3B).
LASV-specific Ag, IgM and IgG levels in normal donors
Kenema district is a highly endemic LF region of Sierra
Leone; therefore, collecting a representative sample
population of Sierra Leonean normal controls in
Kenema with low exposure to LASV was not possible.
Instead, a panel of 101 sera samples was collected in
April 2010 from individuals in the Southwestern pro-
vince of Moyamba, described in the literature as a non-
Figure 1 Lassa virus antigen levels in LF patients. Serum levels
of LASV NP antigen in LF patients were quantitated by ELISA, using
a sensitive caprine polyclonal antibody capture and detection
sandwich method [11,12]. Follow-up convalescent patients primarily
displayed undetectable levels of LASV antigen. Viral antigen levels
between nonfatal (LF NF) and fatal LF cases (LF F) were significantly
different at the time of admission or testing (N = 87, p < 0.01). The
average time from onset of symptoms to admission was 8.0 ± 3.7
days for LF NF patients, and 10.4 ± 4.5 days for LF F patients. The
difference between these times was not statistically significant (p =
0.07).
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endemic region for LF [2,8,16-23], for analysis of LASV
Ag, IgM, and IgG profiles (Additional File 2A,B, Figure
2). Additionally, 13 sera samples were obtained from
donors in the Northeastern province of Bombali, which
is also purported to be a non-endemic region for LF in
Sierra Leone (Additional File 2A,B, Figure 2) [2,8,16-23].
All donors were interviewed prior to blood drawings
and all reported normal health status with no recent
febrile illnesses. All 101 sera from Moyamba and 13 sera
from Bombali were negative for LASV NP Ag (Addi-
tional File 2C). Conversely, after applying a correction
factor based on the limit of detection (LoD) of the
assays, 28 (27.7%) of the Moyamba samples tested posi-
tive for IgM, 63 (62.4%) tested positive for IgG, and 18
(17.8%) tested positive for both IgM and IgG (Additional
File 2C). For the 13 Bombali samples, 3 (23.1%) tested
positive for IgM, 12 (92.3%) tested positive for IgG, and
3 (23.1%) tested positive for both IgG and IgM (Addi-
tional File 2C). Specificity of the IgM and IgG ELISA
binding data was confirmed by western blot analysis on
recombinant LASV antigens with normal Moyamba and
Bombali sera and by homologous antigen competition
ELISA (Garry et al, unpublished data). Additionally,
depletion of IgG from serum abrogated detection of
LASV-specific IgG binding to antigens by ELISA (NP,
GPC, Z protein combinations), but did not significantly
affect relative levels if IgM binding to the same proteins
(data not shown). Moreover, a blinded panel of sera
from 50 female and 50 male donors obtained from U.S.
sources tested negative for LASV NP Ag and virus-spe-
cific IgM and IgG Ab (Figure 2).
Pre-existing humoral response to LASV in normal
populations compared to diagnosed LF patients
IgM levels were not significantly different between LF
FU and Bombali donors, but they were significantly
higher for LF FU donors than for Moyamba donors (p <
0.001; Figure 2A). Similarly, LF FU patients had higher
IgG levels than Moyamba normal donors (p < 0.001)
but they did not differ from Bombali donors (Figure
2B). Furthermore, LF FU patients showed significantly
higher IgG levels than LF NF (p < 0.001) and LF F (p <
0.001) patients at the time of diagnosis (Figure 2B).
These data suggest that (1) most symptomatic and acute
LF patients presenting to KGH LFW are naïve to LASV;
(2) exposure to LASV in Sierra Leone is more prevalent
than previously reported and remains mostly undiag-
nosed; (3) regions of Sierra Leone previously considered
non-endemic for LF revealed a significant level of
LASV-specific IgM and IgG prevalence.
Table 2 Characteristics of study subjects analyzed for cytokines and clinical chemistrya
Characteristic LF F (N = 25) LF NF (N = 19) NL FI IgM+ (N = 21)
Age < 15 yrs 11 (44) 5 (26) 6 (30) †
15 - 40 yrs 14 (56) 10 (53) 10 (50)†
> 40 yrs 0 (0) 4 (21) 4 (20)†
Gender Male 12 (48) 7 (37) 6 (29)
Female 13 (52) 12 (63) 15 (71)
Duration of illness < 3 days 18 (72) 1 (5)b* 2 (11)†d*
≥ 3 days 7 (28) 18 (95) 16 (89)†
Major Signs Fever 24 (100) † 19 (100) 17 (94)†
Bleeding 9 (36) 2 (11)c 1 (6)†e*
Head swelling 7 (28) 4 (21) 1 (6)†
Conjunctivitis 5 (20) 5 (26) 1 (6)†
a All results expressed as frequency (%), unless noted otherwise. Odds ratios (ORs) and their associated 95% confidence intervals were calculated using ordinary
logistic regression.
b Odds of fatal outcome in LF F versus LF NF for the interval between date of admission and date of death or discharge is 46.3 (5.2, 415.6), which is significant.
c Odds of fatal outcome in LF F versus LF NF for the presence versus absence of bleeding symptoms is 5.1 (0.9, 27.4), which is not significant.
d Odds of fatal outcome in LF F versus NL FI IgM+ for the interval between date of admission and date of death or discharge is 14.4 (2.48, 80.68), which is
significant.
e Odds of fatal outcome in LF F versus NL FI IgM+ for the presence versus absence of bleeding symptoms is 9.56 (1.09, 84.24), which is significant.
† Data unavailable for all observations.
* Significant at the 5% significance level.
The characteristics of three groups were compared based on antigen status and death. Ag+ LF patients were separated into two groups based on survival status.
Age, gender and all but one of the major signs of LF appeared not to impact survival rates in LASV Ag+ patients. Odds ratio for duration of illness, however, was
significantly different at the 5% significance level between those who survived LF and those who succumbed. Additionally, each LF group was compared to
individuals who were suffering from a febrile illness that could not be definitively diagnosed as LF based on an Ag-IgM+ profile. There were no significant
differences between LF NF and NL FI IgM+ groups amongst the various characteristics examined. Significant differences arose between LF F and NL FI IgM+
groups for duration of illness and bleeding. Ultimately, for both comparison groups, if individuals survived past day three after admission and initiation of
treatment then their chances of survival increased significantly (OR = at least 5.2, statistically significant between LF F vs. LF NF; OR = at least 2.48, statistically
significant between LF F vs. NL FI IgM+). Additionally, Ag+ patients who presented with bleeding symptoms were more likely to succumb (OR not statistically
significant between LF F vs. LF NF; OR = at least 1.09, statistically significant between LF F vs. NL FI IgM+).
Branco et al. Virology Journal 2011, 8:478
http://www.virologyj.com/content/8/1/478
Page 6 of 15
Circulating inflammatory mediators and metabolic panel
in Lassa fever
Evaluation of pro- and anti-inflammatory cytokines, che-
mokines, growth factors, and disease state metabolite
indicators revealed statistically significant to highly sig-
nificant differences between LF patients and non-LF
controls in the levels of interleukin (IL) -10, IL-8, IL-6,
macrophage inflammatory protein 1 beta (MIP-1b) (Fig-
ure 4), blood urea nitrogen (BUN), total carbon dioxide
(tCO2), calcium (Ca
2+) corrected for albumin (ALB),
alkaline phosphatase (ALP), alanine aminotransferase
(ALT), and aspartate aminotransferase (AST) (Figure 5)
in LF patients compared to non-LF controls. Other mar-
kers, such as interferon gamma (IFN-g) (Figure 4), IL-4,
Figure 2 IgM and IgG responses for normal donors, LF and NL febrile subjects. Box plots of LASV-specific IgM (A) and IgG (B) levels
determined by ELISA, are displayed as mean OD450 with corrected cutoff values based on the 95
th percentile of established negative control
sera. Each display shows the minimum non-outlying value, three quartiles, maximum non-outlying value, and outlying values. The comparison
groups include U.S. normals (US N), Moyamba district normals (MOY NHS), Bombali district normals (BOM NHS), convalescent LF follow-up
patients (between 8 and 108 weeks post discharge [LF FU]), nonfatal acute LF cases (LF NF), fatal LF cases (LF F), and non-Lassa febrile illness
with LASV-specific IgM only (NL FI IgM+). IgM and IgG levels for patients in the LF FU sera group were significantly higher than those in for all
of the other comparison groups, save for those in the BOM NHS and NL FI IgM+ cohorts. There were no significant differences between LF NF
and LF F cases for both IgM and IgG responses. Bombali sera showed relatively high levels of LASV-specific IgM and IgG, but these levels did not
significantly differ from those for LF FU patients, despite their undiagnosed recent LF or other febrile illnesses. Outliers are indicated with red
asterisks (*). Significant p values for pairwise comparisons are displayed as * p < 0.05; ** p < 0.01; and *** p < 0.001.
Branco et al. Virology Journal 2011, 8:478
http://www.virologyj.com/content/8/1/478
Page 7 of 15
and creatinine (CRE) (data not shown) showed wider
ranges of increased expression in fatal cases than nonfa-
tal cases, but the differences in median expression levels
were not statistically different. Similarly, statistical differ-
ences were not observed between fatal and nonfatal LF
cases for levels of IL-1b, which tended to be lower than
normal for both fatal and nonfatal LF groups (data not
shown). IL -6 and -10 were significantly higher for fatal
LF cases than normal, nonfatal, and follow-up donors,
but differences were not observed between nonfatal LF
and normal controls (Figure 4). MIP-1b was significantly
less for only fatal cases as opposed to nonfatal cases, but
did not differ between fatal cases and normals (Figure
4). Cytokines IL-12p70, IL-2, IL-5, TNF-a, TNF-b, and
IFN-a did not appear to be influential in the pathogen-
esis of LF (Figure 4 and data not shown). Albumin
(ALB) levels were not significantly different between
fatal and non-fatal LF, but in both cases were signifi-
cantly lower than in normal controls (data not shown).
Total serum protein (TP) levels, however, were signifi-
cantly less than normal for fatal LF cases (data not
shown). Total bilirubin (TBIL), and levels of chloride
(Cl-), potassium (K+), and sodium (Na+) ions were not
significantly dysregulated in LF (data not shown). BUN,
ALP, AST, and ALT were all highly elevated in fatal LF,
but not significantly different between non-fatal LF and
normal subjects (Figure 5). Calcium (Ca2+) levels in
non-fatal and fatal LF were significantly higher than
normal after correcting for albumin levels (Figure 5).
The most significant prognostic marker of fatal outcome
in LF was highly elevated AST. All LF subjects who met
with a fatal outcome in this study with the exception of
one low outlier presented with extremely high levels of
AST (Figure 5). The LF convalescent group displayed
cytokines and metabolic markers similar to those
recorded in normal individuals, with the exception of
IL-6, which showed a higher range than normal donors,
but the median IL-6 level for the convalescent group
was not statistically significant (Figure 4).
LASV IgM+ Ag- febrile subjects present with
inflammatory and metabolic profiles different from those
of LF F but not LF NF patients
NL FI IgM+ subjects presented to the hospital with
fever, and in some instances bleeding and conjunctivitis,
all of which are major symptoms of LF (Table 2). These
patients registered low LASV-specific IgG titers (Figure
2B), and all were negative for viral antigen. Cytokine
profiles were unremarkable when compared to LF NF,
with the exception of MIP-1b, which was significantly
elevated in NL FI IgM+ subjects (Figure 4). No signifi-
cant differences were observed in levels of metabolic
indicators between LF NF, NL FI IgM+, and normal
donors (Figure 4, 5). Conversely, the LF F and NL FI
IgM+ groups differed significantly in most cytokines and
metabolic indicators, with the exception IL-6, MIP-1b,
IL12p70, and corrected Ca2+ levels (Figure 4, 5). The
most remarkable trait recorded in the NL FI IgM+
patient subset was the absence of detectable LASV Ag
or nucleic acid. The attending physician closely moni-
tored the 21 patients in this group after testing for
LASV Ag and immunoglobulins, but only 4 were treated
with ribavirin. Notably, treatment of patients is at the
discretion of the attending physician; febrile and LASV
Ag- IgM+ patients presenting with additional symptoms
of LF infection may be treated with ribavirin. In this
group 3 subjects expired shortly after admission (N = 2,
Figure 3 Regression analysis for IgM and IgG responses
against number of days post-discharge for convalescent LF
patients. Corrected mean OD450 values for LASV-specific IgM (A.)
and IgG (B.) levels in LF convalescent patients did not reveal any
dependence with time post-discharge for immunoglobulins
responses. Hypothesis tests for the slope of each regression line
revealed zero slopes for both profiles, suggesting that IgM and IgG
responses for convalescent patients remained relatively constant
after discharge. The fitted intercept for the regression line shown in
(A.) was 0.46 (SE = 0.09), which showed prolonged elevation in IgM
responses for convalescent LF patients. The fitted intercept of 1.14
(SE = 0.06) for (B.) was indicative of a prolonged mature humoral
response (IgG) in convalescent LF patients.
Branco et al. Virology Journal 2011, 8:478
http://www.virologyj.com/content/8/1/478
Page 8 of 15
Figure 4 Levels of relevant cytokines in LF pathogenesis. Serum levels of IL-8, Il-6, IL-10, and MIP-1b showed significant differences between
LF NF and LF F patients on admission. For LF NF patients, IL-8 levels were significantly reduced when compared to LF F, normal, and LF FU
subjects. Elevated levels of IL-6 and IL-10 were recorded in LF F patients, but were significantly lower in LF NF subjects. MIP-1b was significant
reduced in LF NF only when compared to LF F patients. Interferon-g was significantly higher for fatal LF patients than normal donors and follow-
up controls, but IFN-g levels did not differ between fatal and nonfatal LF patients. Similarly, IL12p70 levels were significantly elevated in LF F
when compared to normal donors, but did not differ from the other comparison groups. CD40L was significantly reduced in LF NF when
compared with normal controls, but not in LF F. Cytokine levels were relatively similar between LF NF and NL FI IgM+ groups, with the
exception of MIP-1b, which was elevated in the later cohort. Outliers are denoted with red asterisks (*). Significant p values for pairwise
comparisons are denoted as * p < 0.05; ** p < 0.01; and *** p < 0.001.
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Figure 5 Relevant metabolic indicators in LF pathogenesis. Hepatic enzymes ALP, ALT, and AST were highly elevated in LF patients,
particularly for LF F patients. AST levels were the best prognosticator in LF, with nearly all fatal cases showing extremely high levels. Dissolved
tCO2 levels were significantly lower than normal for LF F patients, whereas BUN levels were significantly higher than normal. Serum calcium
levels (corrected for serum albumin levels) were elevated in LF patients regardless of eventual outcome, but no differences in elevation were
observed between acute LF groups. Lower and upper outliers are denoted with pink and red asterisks (*), respectively. Significant p values are
denoted as * p < 0.05; ** p < 0.01; *** p < 0.001.
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4 days to expiry; N = 1, 0 days to expiry), 4 were dis-
charged (N = 2, 10 days; N = 1, 4 days; N = 1, 3 days),
and 14 were not admitted.
Discussion
Historically, LASV viremia has been the primary marker
of acute infection as assessed by Ag-capture ELISA,
LASV RNA detected by RT-PCR or virus culture (the
latter serving as the “gold standard”). Alternatively, ele-
vated LASV-specific IgM has served as a surrogate mar-
ker of a recent infection when LASV Ag could no
longer be detected [24]. With little known about LASV-
specific humoral immune responses and immunopathol-
ogy, the rationale for considering IgM positivity as acute
LASV infection was based on observations in other
pathogenic infections in which a drop in antigen levels
coincided with increasing IgM titers that class switched
to a predominantly IgG status within weeks of initial
infection. Given the low rate of IgM and IgG seroposi-
tivity in healthy blood donors from the United States,
IgM seropositivity in non-Africans recently traveled to
LF endemic regions of West Africa is a likely indication
of a recent LASV infection. Results presented herein,
however, suggest that LASV-specific IgM seropositivity
in the absence of viremia should not be considered as a
diagnostic marker for acute LF in the regions of West
Africa where evidence of a high prevalence of LASV-
specific seropositive status exists.
Because Kenema is historically endemic for LASV, we
looked to the Northeastern and Southwestern districts
of Bombali and Moyamba, respectively, to collect a
panel of normal Sierra Leonean serum. These districts
lie within reportedly non-endemic areas so exposure to
LASV should be low. The donors from these two
regions reported normal health at the time of blood
draw without febrile episodes in the recent past, and
had not travelled to the Eastern provinces where LF is
endemic. Contrary to our expectations, a significant per-
centage in each population had LASV-specific IgM and
IgG titers indicating a past infection with LF. Our find-
ings challenged past reports claiming that LF is highly
endemic primarily in the Eastern districts of Sierra
Leone, and is largely absent in the country’s Northern
and Southern regions (Additional File 2A, B). It is note-
worthy that in the past one year a significant number of
suspected LASV cases from Bombali have been referred
to the KGH, with several being confirmed as LF [12].
Identification of suspected LF cases has been made pos-
sible by increased awareness of the disease by medical
staff in Bombali district hospitals and the availability of
rapid diagnostics provided by the VHF consortium.
These surprising results prompted us to reevaluate the
categorization and analysis of Ag and IgM status in a
suspected LF patient database compiled at the KGH
LFL between 2006 and 2011. To determine whether
IgM status could be used as a diagnostic marker, we
compared the odds ratios of a group of LASV Ag+
patients and LASV Ag- patients. This revealed that,
regardless of IgM status, the fatality rate was signifi-
cantly higher in Ag+ patients compared to Ag- patients
(Ag+IgM+ v. Ag-IgM+ OR = 4.33, p < 0.01; Ag+IgM- v.
Ag-IgM- OR = 5.36, p < 0.01). Additionally, we found
that positive LASV IgM seropositivity is not a reliable
marker of acute LF base on the adjusted odds ratio of
1.13 in Ag-IgM+ (N = 171) versus Ag-IgM- (N = 244)
in suspected LF patients (p = 0.61, Table 1). Conversely,
Ag+ status, irrespective of IgM status, was indicative of
a poor outcome, with approximately 55% of patients
succumbing to LF. This percentage is higher than the
historical and consistently reported death rate of
approximately 15-20% because we eliminated a large
population of patients that could not be considered as
acute infections with LASV [25-28]. We believe that
55% is a more accurate fatality rate based on the pro-
longed LASV-specific IgM response found in convales-
cent patients months to years following LASV infection
(Figure 2) [11,12]. Our data show that detectable LASV
viremia assessed by Ag seropositivity is highly correlated
with acute viral infection, while IgM shows no such
correlation.
There are several potential interpretations for sus-
tained LASV-specific IgM titers [29-33]: 1. IgM may be
indicative of a recent infection for which class switching
has not fully occurred; 2. A prolonged and as of yet lar-
gely uncharacterized inhibition of class switching could
be prevalent in LASV infections (Grove, Garry et al.,
unpublished data); 3. Sustained IgM titers could be gen-
erated by IgM+ memory B cells; 4. Impaired CD4+ T
helper lymphocyte function during LASV infection, with
long-term impact on class switching may be central to
humoral and cellular immunity aspects in LF; (5) Indivi-
duals may be infected with LASV but clear viremia
without treatment, and seek medical intervention too
late for detection of virus antigen by LFI, ELISA, and
nucleic acid by PCR.
Evidence for these mechanisms can be found in the
literature. Non-neutralizing virus-specific IgM were
recently analyzed and deemed crucial for impedance of
viral persistence in LCMV infection (the prototypic Old
World arenavirus), suggesting that IgM-producing cells
have remained largely obscure and underappreciated in
the characterization of arenaviral infections [34]. Addi-
tionally, the late appearance of neutralizing antibodies in
arenaviral infections has been tied to high viral antigen-
to-B cell ratios and low T cell help, which resulted in a
normal IgM response but reduced the efficiency of class
switching [35]. Lowering the antigen-to-B cell ratio and
increasing T cell help resulted in rescuing of class
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switching and emergence of neutralizing IgG specifici-
ties. Thus it is possible that a normal early IgM
response in LASV infections is followed by an impaired
T helper cell response with sustained IgM production
and eventual maturity of the producing B cell subset
into an IgM+ B cell memory population. The role of
IgM and T-helper lymphocytes have been studied in
controlled cynomolgus macaque models of SIV infection
[36]. These studies noted a strong inverse correlation of
the immunoglobulin and CD4+ T helper cell counts
after the primary peak of IgM response, reflecting the
prevalence of mature plasma cells that have not under-
gone class switching. Moreover, a strong correlation was
observed in the same studies between pre-infection
immune status and disease progression. It is therefore
possible in arenaviral infections, as in the SIV model,
that a normal, pre-infection CD4+ T helper cell thresh-
old may regulate normal B cell responses, with conco-
mitant class switching, emergence of strong neutralizing
IgG titers, and quiescence or elimination of short lived
IgM-producing plasma cells. We have recently reported
on two cases of severe LF [11,12] that registered increas-
ing IgM titers throughout hospitalization and for
months into convalescence. Virus-specific IgMs were
invariably paralleled by rising, albeit temporally delayed,
IgG titers. We have observed similar circulating Ig pat-
terns in numerous other LF cases, with rising IgG titers
following an initial IgM response. Interestingly, in the
21 NL FI IgM+ subjects we did not record LASV-speci-
fic IgG titers, despite prolonged hospitalization and mul-
tiple sera testing for a subset of patients (Figure 2 A, B).
Therefore, it appears that in this group of patients
LASV-specific IgM responses were indicative of a pre-
vious infection with muted class switching.
In the Ag positive subset of patients, remarkable dif-
ferences were noted in cytokine and metabolite levels
that could be used as early prognosticators in LF. Our
results have confirmed historical reports demonstrating
significant hepatic and renal dysfunction in LF, namely
the high levels of ALP, ALT, and AST [30-39]. However,
not all of our cytokine and metabolite observations fol-
low the historical observations from the literature.
Mahanty et al. previously reported that elevated levels of
IL-8 and IP-10 correlated with positive outcomes in LF
[24], while we observed that low levels of IL-8 and other
cytokines to be correlates of survival outcome. The fre-
quent exposure of populations to parasitic infections is a
likely factor in the elevated levels of recorded IL-8 in the
sampled normal and non-Lassa febrile groups, a phe-
nomenon not commonly observed in U.S. blood donors
(Figure 4). Although there was not a significant reduc-
tion in the overall levels of IL-8 between normal donors
and fatal LF patients, a significant drop in the levels of
this cytokine was observed in all patients who survived
LF (excepting a single, high outlier). Thus our data from
this report and others [37-39] suggest that a regulated
quiescence of the inflammatory response, in addition to
a robust humoral immune response may be central to a
successful outcome in symptomatic acute LF. In addi-
tion to IL-8, low levels of IL-6, IL-10, MIP-1b, and
CD40L were predictive of survival. A subset of indivi-
duals presenting with a non-Lassa febrile illness that
may have registered LASV-specific IgM titers were not
included in our acute LF study group, but were included
in the acute LF population studied by Mahanty et al.
[24]. The differences between our studies and those by
Mahanty et al. [24] and others may therefore rest on the
parameters employed in classifying acute LF.
Our analysis of a nonfatal non-Lassa febrile illness (NF
NL FI) study group revealed levels of IL-8 similar to
those in the LF NF and LF F groups, despite observing
increased levels of the inflammatory mediator in some
subjects (Figure 4). The only inflammatory marker ana-
lyzed in our studies that differentiated LF from other
FIs was IL-6, which was increased in LF F relative to all
other comparison groups (Figure 4). Interestingly, in the
NL FI IgM+ (and IgG- Ag-) group we observed reduced
levels of IL-8 and elevated levels of MIP-1b, as well as
metabolic indicators that did not significantly differ
from those in LF NF. A comparable profile of inflamma-
tory mediators was observed in a study of LF pathogen-
esis in cynomolgus macaques, which revealed that
elevated levels of IL-6 conferred a poor prognosis, while
IL-8 and IL-10 responses were largely absent [40].
Together, these data indicate that upon admission to
the hospital with suspicion of LF, a profile of low to
moderate IL-6, -8, -10, MIP-1b, CD40L, BUN, ALP,
ALT, and AST levels predict a positive outcome follow-
ing treatment with a full regimen of ribavirin, fluids
management, antibiotics, and other appropriate medical
intervention. Conversely, AST levels greater than 2000
U/mL are almost always indicative of a poor survival
outcome. In addition to high AST, combined elevated
IL-6, -8, -10, BUN, ALP, ALT, and reduced tCO2, Ca
2+,
RANTES, and CRP levels provide a statistical basis for
poor prognosis. Two recent extensively-characterized
reports of hemorrhagic LF in Sierra Leone with positive
outcome presented to the KGH LFW with AST > 2000
U/mL and low levels of IL-6, -8, and in one case ele-
vated IL-10 [11,12]. Based on the data presented herein,
the prognosis for both patients would have been poor,
yet, with a relatively short timeframe from onset of
symptoms to presentation to the KGH LFW (6 and 7
days, respectively) and proper medical interventions,
both patients survived. The data collected in these stu-
dies generated statistically relevant correlates of LF out-
come, but have also exposed gaps in our current
understanding of relevant biomarkers for LF. The
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observed pronounced quiescence of the inflammatory
response in surviving LF patients may present new
opportunities for future disease treatment and manage-
ment. It is conceivable that administration of anti-
inflammatory drugs to quiesce the cytokine storm
observed in LF may complement the beneficial effects of
reducing viral loads with ribavirin treatment, thus
increasing survival rates in acutely infected patients.
Limitations of this study include lack of randomiza-
tion, limited number of fatal Lassa cases, potential
patient by treatment interaction, and the limited dura-
tion of the study. Random assignment of subjects to
comparison groups was not possible due to the
uncontrollable nature of the outcome, and random
selection of patients was impractical due to the limited
number of fatal Lassa cases. As a result, some of the
results that we observed may be due to inherent charac-
teristics of our study subjects. This is perhaps most evi-
dent in the 13 normal donors from Bombali that
registered greater than 90% IgG reactivity to LASV anti-
gens. It is important to note that these limited studies
were not designed to ascertain levels of IgM and IgG
seroprevalence in Sierra Leonean populations. Instead,
through the continuous analysis of incoming sera from
patients and random collection of normal samples in
two districts outside historically endemic regions, it was
established that LASV infections in humans might be
more prevalent across Sierra Leone than previously
reported. In the case of Bombali donors we may have
collected sera from a cluster of individuals who may
have had an unknown exposure bias to LASV, thus
registering high levels of IgG (and possibly IgM) to viral
antigens. We suspect our study subjects are more likely
to have multiple exposures to LASV than subjects from
previous studies due to the increasing prevalence of the
disease. Due to the small sample sizes for each of the
comparison groups, we were unable to adjust for con-
founding variables, which makes the generalization of
these findings inappropriate, particularly for those out-
side of Sierra Leone. Although all of the patients in this
study were subjected to the same treatment protocol, it
is unknown whether the treatment was administered in
a consistent manner and whether patients responded
differently to the ribavirin treatment. A randomized trial
on the effect of ribavirin would be beneficial to future
studies on Lassa fever. It is worth noting that there is a
temporal component for the outcomes investigated in
this study that is not well understood.
Due to our characterization of a prolonged IgM
response in convalescent LF patients, high prevalence of
IgM seropositive in healthy normal controls, and the
failure of most IgM only suspected cases to display a
dysregulated metabolic and inflammatory cytokine pro-
file similar to LASV-specific Ag+ patients regardless of
IgM status, we suggest that the traditional paradigm for
diagnosis of acute LF in West Africa should be recon-
sidered and changed. Rather than diagnosing an Ag+
and/or IgM+ result as acute LF, only in the subset of
patients displaying LASV viremia, as determined by LFI
and Ag-capture ELISA, with confirmation by RT-PCR
should be definitively categorize a patient as being
acutely infected with LASV. Patients that presented with
symptoms indicative of potential LF and who do not
test positive for viremia by any of the three methods
employed while presenting with IgM and/or IgG titers
should not be categorized as acute LF. Unfortunately,
ultimate diagnosis of the non LF febrile illness for these
patients will often not be possible due to low resources
and lack of diagnostics for additional suspected infec-
tious agents. Though, the new prognostic immune cor-
relates of LF identified in this study will allow the
scientific community to better understand, monitor, and
possibly treat and prevent the disease.
Additional material
Additional file 1: Complete characteristics of study subjects
analyzed for cytokines and clinical chemistry. An expanded set of
groups was analyzed for age, gender, duration of illness, and major signs.
Corresponding odds ratios are shown, and asterisks (*) indicate
significance at the 5% level.
Additional file 2: Map of West Africa displaying calculated rates of
LASV Ag, IgM, IgG, and dual antibody in sera samples obtained
from Sierra Leonean Districts of Moyamba and Bombali. (A) Districts
of Sierra Leone: the historically hyperendemic districts of Kenema and
Kallahun are circled in blue, and the Northern and Southern districts of
Bombali and Moyamba are underlined in red. A map outlining Sierra
Leone’s four provinces is shown in (B). The relative locations in Sierra
Leone where panels of normal sera study samples were collected are
boxed in red. Antigen and immunoglobulin rates for locations sampled
in this study are outlined in insets. Numbers of sera analyzed from each
region are noted (N). Serological evidence of LF has been reported in
Senegal and Mali (denoted with solid blue circles), and outbreaks are
commonly reported in endemic regions of Sierra Leone, Guinea, and
Liberia (denoted with solid red circles). The relative sub-Saharan
geographical boundary for LF is outlined by the thick transparent orange
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